Erin K. Brenner - 09 Dec 2022 Form 4 Insider Report for Pear Therapeutics, Inc.

Role: Chief Product Dev. Officer
Signature: /s/ Stacie S. Aarestad, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 09 Dec 2022
Net transactions value: +$15,000
Form type: 4
Filing time: 09 Dec 2022, 16:02:41 UTC
Previous filing: 27 May 2022
Next filing: 18 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PEARQ	Common Stock	Options Exercise	$15,000	+15,000	+100%	$1.00^*	30,000	09 Dec 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PEARQ	Stock Option (Right to Buy)	Options Exercise		-15,000	-14%		90,234	09 Dec 2022	Common Stock	15,000	$1.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	100% of the shares subject to this option are fully vested and exercisable.
F2	Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 81,659 shares of common stock of Private Pear for $1.46 per share.